IL-1β inhibits self-renewal capacity of dormant CD34+/CD38 acute myelogenous leukemia cells in vitro and in vivo.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      We previously showed that CD34+/CD38 acute myelogenous leukemia (AML) cells, which contain leukemia stem cells, expressed a greater amount of the phosphorylated forms of JAK2 and STAT5 (p-JAK2 and p-STAT5) than their CD34+/CD38+ counterparts. To identify candidate cytokines that are involved in the activation of JAK2/STAT5 in CD34+/CD38 AML cells, we compared the cytokine expression profiles of CD34+/CD38 AML cells and their CD34+/CD38+ counterparts. Interestingly, freshly isolated CD34+/CD38 AML cells from patients ( n = 17) expressed less interleukin-1β (IL-1β) than their CD34+/CD38+ counterparts and CD34+ normal hematopoietic stem/progenitor cells from healthy volunteers ( n = 6), as measured by real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Methylation-specific PCR found that IL-1B gene expression was silenced by methylation of the promoter region. Importantly, exposure of CD34+/CD38 AML cells to IL-1β (100 ng/ml) stimulated cell-cycle progression, induced apoptosis and sensitized these cells to growth inhibition by antileukemia agents. These changes occurred in conjunction with the downregulation of cyclin-dependent kinase inhibitor p21 waf1, antiapoptotic proteins and p-STAT5. Forced expression of IL-1β in CD34+/CD38 AML cells by lentiviral transduction significantly impaired the self-renewal capacity of the cells and induced apoptosis. Additionally, when these CD34+/CD38 AML cells with forced expression of IL-1β were transplanted into severely immunocompromised mice, the engraftment of the cells and reconstitution of AML were significantly impaired. Taken together, our results indicate that the inhibition of STAT5 by IL-1β may be a promising treatment strategy to eradicate leukemia stem cells in AML. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of International Journal of Cancer is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)